- Home
- THCH vs PRLD Comparison
THCH vs PRLD Comparison
Compare THCH & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- PRLD
- Stock Information
- Founded
- THCH 2018
- PRLD 2016
- Country
- THCH China
- PRLD United States
- Employees
- THCH N/A
- PRLD N/A
- Industry
- THCH Blank Checks
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- THCH Finance
- PRLD Health Care
- Exchange
- THCH Nasdaq
- PRLD Nasdaq
- Market Cap
- THCH 123.1M
- PRLD 110.0M
- IPO Year
- THCH N/A
- PRLD 2020
- Fundamental
- Price
- THCH $0.72
- PRLD $1.92
- Analyst Decision
- THCH
- PRLD Buy
- Analyst Count
- THCH 0
- PRLD 3
- Target Price
- THCH N/A
- PRLD $5.33
- AVG Volume (30 Days)
- THCH 109.7K
- PRLD 231.0K
- Earning Date
- THCH 11-13-2024
- PRLD 10-30-2024
- Dividend Yield
- THCH N/A
- PRLD N/A
- EPS Growth
- THCH N/A
- PRLD N/A
- EPS
- THCH N/A
- PRLD N/A
- Revenue
- THCH $210,072,270.00
- PRLD N/A
- Revenue This Year
- THCH N/A
- PRLD N/A
- Revenue Next Year
- THCH N/A
- PRLD N/A
- P/E Ratio
- THCH N/A
- PRLD N/A
- Revenue Growth
- THCH 12.63
- PRLD N/A
- 52 Week Low
- THCH $0.57
- PRLD $1.66
- 52 Week High
- THCH $2.30
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- THCH 47.53
- PRLD 30.18
- Support Level
- THCH $0.62
- PRLD $1.87
- Resistance Level
- THCH $0.78
- PRLD $2.01
- Average True Range (ATR)
- THCH 0.07
- PRLD 0.12
- MACD
- THCH -0.01
- PRLD 0.10
- Stochastic Oscillator
- THCH 42.61
- PRLD 29.41
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. It is also the operator and developer of Popeyes brand in Mainland China. The firm has two reportable segments; Tim Hortons which generates key revenue, and Popeyes. The company's revenue is derived from its operations in the PRC.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.